Pharmaceuticals

Indonesia BPOM Issues Regulation No. 5/2026 on Oversight of Medicines Management in Pharmacy Facilities

In March–April 2026, Indonesia’s BPOM adopted Regulation No. 5/2026 establishing binding supervision rules for how medicines and medicinal materials are managed in pharmacy service facilities and certain other facilities. This replaces BPOM Regulation No. 24/2021, so pharmacy operators should update SOPs, training, and records to align with the new oversight framework ahead of inspections.

10 Apr 2026, 15:54jdih.pom.go.idIndonesia

Brazilian Chamber Health Committee Reviews PDPs to Boost National Medicines Production

In April 2026, Brazil’s Chamber Health Committee used a public hearing on PDP partnerships to showcase resumed national production of key medicines and vaccines and to highlight Bill PL 2583/2020, which would create a National Health Strategy and formalise incentives for domestic manufacturers. If PL 2583/2020 advances, Strategic Health Enterprises (EES) could gain a 20‑year special tax regime and up to 10% bid preferences in public procurement, strengthening the business case for locating high‑tech pharmaceutical production and PDP-based technology‑transfer projects in Brazil.

10 Apr 2026, 15:36portalmt.com.brBrazil

Philippines FDA Opens Consultation on Validity Extensions for Pharmaceutical Registrations Under AOs 2024-0012 and 2024-0013

The Philippines FDA has issued draft amendments to Administrative Orders 2024‑0012 and 2024‑0013 to extend and add flexibility to the validity periods of export-only certificates and domestic certificates of product registration for pharmaceutical products, with stakeholder comments due by 05 June 2026. If adopted, these changes would give manufacturers and marketing-authorisation holders longer and configurable registration cycles (up to 12 years) for both export and human-use products, reducing renewal workload while tightening reliance on valid licences to operate and GMP compliance to keep market and export authorisations in force.

10 Apr 2026, 15:26fda.gov.phPhilippines

Brazil ANVISA Issues IN 433/2026 to Expand Radiopharmaceutical Registrations

ANVISA has issued IN 433/2026, updating Brazil’s radiopharmaceutical lists so 57 diagnostic and therapeutic products can use published clinical literature to demonstrate safety and efficacy under RDC 738/2022, with the instruction taking effect on 06 April 2026. This creates a clearer and potentially faster registration pathway for radiopharmaceutical manufacturers and importers in Brazil, supporting innovation and supply resilience in nuclear medicine while reducing data and time burdens for eligible products.

10 Apr 2026, 15:25anvisalegis.datalegis.netBrazil

Netherlands Proposes Listing Nitazenes Group and Isotonitazepyne Under Opium Act

The Netherlands has proposed a decree to add the nitazenes group of synthetic opioids to list IA of the Opium Act and to schedule the highly potent opioid isotonitazepyne on list I, with an explanatory memorandum now before Parliament (dossier 24077/559). If adopted, this will significantly tighten controls on emerging synthetic opioids, requiring additional Opium Act exemptions and permits for laboratories, healthcare institutions, and other operators handling controlled opioids in the Netherlands.

10 Apr 2026, 13:02zoek.officielebekendmakingen.nlNetherlands

Netherlands AMvB To Add Isotonitazepyne and Nitazene Opioid Group to Opium Act Lists I and IA

In April 2026, the Netherlands published the text of an order-in-council (AMvB) that will amend the Opium Act by adding the synthetic opioid isotonitazepyne to List I and introducing a structurally defined “benzimidazole opioids (nitazenes)” substance group in List IA. Once the decree is published in the Staatsblad, isotonitazepyne and a broad set of nitazene analogues will become fully controlled under Dutch narcotics law, so manufacturers, laboratories and healthcare providers need to treat any handling or trade as tightly regulated and prepare compliance processes accordingly.

10 Apr 2026, 12:58zoek.officielebekendmakingen.nlNetherlands

US FDA Issues Edition 2 Guidance On Pyrogen And Endotoxins Testing

In March 2026 the US FDA published Edition 2 of its Q&A guidance on pyrogen and endotoxins testing, updating expectations for sampling, method selection, and acceptance criteria across drugs, biologics, veterinary products, and medical devices.[^1^](https://www.fda.gov/media/83477/download) Manufacturers and contract labs should review endotoxin/pyrogen control strategies, pooling practices, and reliance on rabbit pyrogen tests to align with FDA’s risk‑based recommendations and its openness to validated alternative methods.

10 Apr 2026, 10:28fda.govUnited States

European Commission Announces New Global Health Commitments at One Health Summit

In April 2026, the European Commission announced nearly **€800 million** in new global health commitments, combining a €700 million pledge to the Global Fund with targeted One Health, antimicrobial resistance (AMR) and neglected tropical disease investments.[^1^](https://ec.europa.eu/commission/presscorner/detail/en/ip_26_776#:text=The%20European%20Commission%20intends%20to%20pledge%20%E2%82%AC700%20million) These measures reinforce EU leadership on global health security and AMR while signalling the upcoming **Global Health Resilience Initiative**, which will guide future funding priorities and partnerships, particularly with African health systems.[^2^](https://ec.europa.eu/commission/presscorner/detail/en/ip_26_776#:~:text=The%20announcements%20are%20within%20the%20scope%20of%20the%20new%20Global%20Health%20Resilience%20Initiative)

9 Apr 2026, 18:05ec.europa.euEuropean UnionAFR

Northern Ireland Amends GP Prescription Rules For Oseltamivir And Zanamivir

Northern Ireland has removed seasonal notification requirements for prescribing influenza antivirals Oseltamivir and Zanamivir, effective May 1, 2026. This shift to year-round prescribing simplifies market access and clinical availability, reducing administrative barriers for pharmaceutical providers and healthcare services.

9 Apr 2026, 14:33legislation.gov.ukUnited Kingdom

Latvia: Cabinet Amends Regulation No. 304 on Medicinal Products Manufacturing and GMP

Latvia has updated its medicinal product manufacturing and GMP regulations, effective April 2026, with a focus on advanced therapy medicinal products (ATMPs). Manufacturers must implement enhanced traceability systems and ensure Qualified Persons meet new specialized training requirements by late 2028 to maintain compliance and market access.

9 Apr 2026, 14:30vestnesis.lvLatvia

District of Columbia Council Introduces Medical Cannabis Beverage Product Amendment Act of 2026

DC introduced legislation in April 2026 to allow alcohol manufacturers to produce non-alcoholic medical cannabis beverages and permit the import of THC-free cannabinoids. This creates new contract manufacturing opportunities and formalizes supply chain requirements, signaling a shift toward integrated production and stricter oversight of cannabinoid inputs.

9 Apr 2026, 14:22lims.dccouncil.govUnited States

US FDA Issues Warning Letter to Meds For Vets, LLC for Adulterated and Misbranded Compounded Animal Drugs

The FDA issued a warning letter to a veterinary compounder for distributing adulterated and misbranded drugs produced from bulk substances in violation of CGMP standards. This action underscores strict enforcement of Guidance for Industry #256, targeting pharmacies that bypass approved drug channels or fail to maintain rigorous sterile manufacturing protocols.

9 Apr 2026, 14:13fda.govUnited States

US FDA Requires ICH E2B(R3) Format for Postmarketing ICSR Submissions From 1 October 2026

The US FDA will mandate the ICH E2B(R3) data standard for all postmarketing individual case safety reports (ICSRs) submitted via ESG NextGen starting October 1, 2026. Manufacturers must upgrade pharmacovigilance systems and data workflows now to ensure seamless transition and avoid submission rejections when the legacy E2B(R2) standard is retired.

9 Apr 2026, 09:53federalregister.govUnited States

UK and US Agree Arrangement on Pharmaceutical Trade, Pricing and Supply Chains

The UK and US have finalized a bilateral pharmaceutical arrangement, effective April 2026, to significantly increase UK medicine spending and provide US tariff protection for UK exports. This deal improves commercial predictability through higher reimbursement ceilings and rebate caps while signaling deeper regulatory alignment on medical device approvals and supply chain security.

6 Apr 2026, 18:30gov.ukUnited KingdomUnited States

US Imposes Section 232 Tariffs on Patented Pharmaceutical Products and Ingredients

The US has introduced Section 232 national security tariffs of up to 100% on patented pharmaceuticals and active pharmaceutical ingredients, with implementation beginning in July 2026. Companies must immediately assess onshoring feasibility and pricing-agreement eligibility to navigate substantial cost pressures and a clear policy shift toward domestic manufacturing.

6 Apr 2026, 18:29whitehouse.govUnited States

US EPA Releases Draft CCL 6 Listing Microplastics, Pharmaceuticals and PFAS as Drinking Water Threats

The US EPA has proposed the Sixth Contaminant Candidate List (CCL 6), prioritizing microplastics, pharmaceuticals, and PFAS for potential future drinking water regulation. This listing signals an expansion of federal oversight into emerging contaminants, likely driving future monitoring mandates and stricter discharge standards for chemical and pharmaceutical manufacturers.

6 Apr 2026, 16:51epa.govUnited States

FDA Clarifies GLP-1 Compounding Policies as Tirzepatide and Semaglutide Shortages Resolve

The FDA has terminated shortage-based enforcement discretion for tirzepatide and semaglutide, mandating a return to strict FD&C Act compliance for all GLP-1 compounding activities. Market participants must transition from emergency supply flexibilities to standard regulatory frameworks, as high-volume compounding and bulk-API usage now face immediate enforcement risk.

5 Apr 2026, 18:36fda.govUnited States

US House Introduces SUPER BUGS Act To Develop Global Antimicrobial Resistance Strategy

The US House has introduced the SUPER BUGS Act of 2026, proposing a global strategy to accelerate the development and commercialization of medical countermeasures against antimicrobial-resistant pathogens. This signals a shift toward coordinated international funding and streamlined regulatory pathways, creating new market access and partnership opportunities for the pharmaceutical and biotech sectors.

5 Apr 2026, 06:11govinfo.govUnited States

European Directorate for the Quality of Medicines & HealthCare (EDQM) Publishes Reference Standards Monthly Newsletter for March 2026

The EDQM has released 10 new and 17 replacement European Pharmacopoeia reference standards, alongside updated withdrawal timelines for existing batches through 2027. Quality control teams must synchronize testing protocols with these updated benchmarks and manage inventory transitions to maintain regulatory compliance and product integrity.

Netherlands Reports Progress on Medicines Availability and Implements Shortage Notification Policy

The Netherlands implemented a mandatory notification policy for medicine supply interruptions on April 1, 2026, as part of a broader strategy to mitigate pharmaceutical shortages. Manufacturers and wholesalers face tighter reporting obligations and must align with emerging national and EU-level requirements for critical medicine buffer stocks and supply chain resilience.

5 Apr 2026, 05:44open.overheid.nlNetherlands